Literature DB >> 27312260

Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought Process.

Bipin Mistry1, Nikunjkumar Patel2, Masoud Jamei2, Amin Rostami-Hodjegan2,3, Marilyn N Martinez4.   

Abstract

The attention and interest in establishing in vivo/in vitro correlations (IVIVCs) is grounded in its tremendous utility as a prognostic tool. It can be used to support formulation optimization, predict in vivo drug exposure across a potential patient population, select a biologically relevant in vitro dissolution test condition, and support the use of in vitro dissolution data as a surrogate for in vivo bioequivalence trials. The pharmacological and statistical implications of this correlation are linked to the method by which the IVIVC was determined and to the assumptions and optimization approaches integrated into the estimation procedure. Using previously published data generated in normal healthy volunteers, an IVIVC for metoprolol was established using a mechanistic modeling approach. Within that framework, we explored the consequences of (1) our method of fitting a single Weibull function to the in vivo dissolution, (2) our selection of weighting scheme and optimization approaches, (3) the impact of applying a fixed versus fitted gastric emptying time, and 4) the importance of factoring population variability into our IVIVC estimation and profile reconvolution. We identified those factors found to be critical in terms of their influence on the accuracy of our predicted systemic metoprolol concentration-time profiles. We considered the strengths and weaknesses of our approach and discussed how the results of this study may impact efforts to generate IVIVCs with compounds presenting physicochemical characteristics different from that of metoprolol.

Entities:  

Keywords:  in vivo/in vitro correlation; mechanistic model; metoprolol

Mesh:

Substances:

Year:  2016        PMID: 27312260     DOI: 10.1208/s12248-016-9930-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  30 in total

1.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

2.  Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

3.  An in vitro-in vivo correlation study for nifedipine immediate release capsules administered with water, alcoholic and non-alcoholic beverages: Impact of in vitro dissolution media and hydrodynamics.

Authors:  A Mercuri; R Fares; M Bresciani; N Fotaki
Journal:  Int J Pharm       Date:  2015-12-22       Impact factor: 5.875

4.  The fraction dose absorbed, in humans, and high jejunal human permeability relationship.

Authors:  Arik Dahan; Hans Lennernäs; Gordon L Amidon
Journal:  Mol Pharm       Date:  2012-05-04       Impact factor: 4.939

5.  Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.

Authors:  S Madani; M F Paine; L Lewis; K E Thummel; D D Shen
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

6.  Development of metoprolol tartrate extended-release matrix tablet formulations for regulatory policy consideration.

Authors:  R V Nellore; G S Rekhi; A S Hussain; L G Tillman; L L Augsburger
Journal:  J Control Release       Date:  1998-01-02       Impact factor: 9.776

7.  pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.

Authors:  Sibylle Neuhoff; Anna-Lena Ungell; Ismael Zamora; Per Artursson
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

8.  Influence of smoking and gender on the disposition kinetics of metoprolol.

Authors:  L J Schaaf; S C Campbell; M B Mayersohn; T Vagedes; D G Perrier
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Determination of dextromethorphan metabolizer phenotype in healthy volunteers.

Authors:  M Hildebrand; W Seifert; A Reichenberger
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions.

Authors:  Alison Margolskee; Adam S Darwich; Aleksandra Galetin; Amin Rostami-Hodjegan; Leon Aarons
Journal:  AAPS J       Date:  2015-12-14       Impact factor: 4.009

View more
  1 in total

1.  Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure.

Authors:  Dwaipayan Mukherjee; Manoj S Chiney; Xi Shao; Tzuchi R Ju; Mohamad Shebley; Patrick Marroum
Journal:  Biopharm Drug Dispos       Date:  2022-05-06       Impact factor: 1.831

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.